Prognostic Factors for Survival in Transverse Colon Cancers.

Transverse colon cancer (TCC) is a rare condition that accounts for 10% of all colon cancers. TCC was accepted more likely right-sided colon cancers. We aimed to investigate whether TCC differs from other colon tumors by using clinical, pathological, and molecular prognostic factors known to be important in colon cancer and if it differs in its own anatomical structure. We evaluated local and locally advanced TCC patients between 2007 and 2020 years for demographics data, symptoms, treatment status, and histopathological and molecular features. Overall, 107 TCC patients were included in this study. According to the molecular data analysis of 44, 35, and 23 patients for MSI, RAS, and BRAF status, respectively, 7 (15.9%) were MSI-H, 13 (37.1%) were RAS mutant, and 11 (47.8%) had BRAF V600E mutation. The median follow-up time was 31.5 months. Median disease-free survival (DFS) was 5.19 months, and median OS was 88.3 months for the whole study population. The tumor stage was the most significant prognostic factor for DFS and OS. Although BRAF mutation was not a significant marker for DFS, it was an independent prognostic marker for OS (HR 3.90 95% CI 1.42-10.7). There were no statistically significant differences between proximal two-thirds and distal one-third tumor location. TCC has molecular features and prognostic factors more likely RCC and no differences between proximal and distal sub-parts. BRAF V600E mutation status is an independent predictor of survival even in the early stages of TCC. © 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Citation

Ahmet Küçükarda, Ali Gökyer, Sezin Sayın, İvo Gökmen, Erkan Özcan, Osman Köstek, Muhammet Bekir Hacıoğlu, Sernaz Uzunoğlu, İrfan Çiçin, Bülent Erdoğan. Prognostic Factors for Survival in Transverse Colon Cancers. Journal of gastrointestinal cancer. 2022 Mar;53(1):31-40

Mesh Tags

Substances

PMID: 34302255

search → result